Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Pyxis Oncology Inc’s stock clocked out at $3.36, up 0.30% from its previous closing price of $3.35. In other words, the price has increased by $0.30 from its previous closing price. On the day, 0.57 million shares were traded. PYXS stock price reached its highest trading level at $3.45 during the session, while it also had its lowest trading level at $3.26.
Ratios:
To gain a deeper understanding of PYXS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.65 and its Current Ratio is at 5.65. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 04, 2025, initiated with a Buy rating and assigned the stock a target price of $5.
On November 08, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $13.Stephens initiated its Overweight rating on November 08, 2024, with a $13 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 21 ’25 when HUMPHREY RACHEL bought 13,896 shares for $1.03 per share.
HUMPHREY RACHEL bought 200 shares of PYXS for $194 on Apr 17 ’25. On Apr 14 ’25, another insider, HUMPHREY RACHEL, who serves as the Director of the company, bought 1,400 shares for $0.97 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 208380928 and an Enterprise Value of 138898928. For the stock, the TTM Price-to-Sale (P/S) ratio is 73.89 while its Price-to-Book (P/B) ratio in mrq is 2.38. Its current Enterprise Value per Revenue stands at 49.255 whereas that against EBITDA is -1.725.
Stock Price History:
The Beta on a monthly basis for PYXS is 1.24, which has changed by -0.0869565 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, PYXS has reached a high of $5.39, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 66.96%, while the 200-Day Moving Average is calculated to be 137.33%.
Shares Statistics:
It appears that PYXS traded 688.37K shares on average per day over the past three months and 1150250 shares per day over the past ten days. A total of 62.02M shares are outstanding, with a floating share count of 44.14M. Insiders hold about 28.82% of the company’s shares, while institutions hold 34.79% stake in the company. Shares short for PYXS as of 1759190400 were 4131340 with a Short Ratio of 6.00, compared to 1756425600 on 4334176. Therefore, it implies a Short% of Shares Outstanding of 4131340 and a Short% of Float of 8.06.
Earnings Estimates
Pyxis Oncology Inc (PYXS) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.25 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$1.14 and -$1.42 for the fiscal current year, implying an average EPS of -$1.28. EPS for the following year is -$1.17, with 7.0 analysts recommending between -$0.78 and -$1.42.
